Viking Therapeutics' strong obesity drug data is fueling acquisition speculation, with analysts viewing it as a top takeover target. Long-time shareholders are satisfied, but potential upside remains. The stock is considered one that could realistically double by 2030, driven by its promising pipeline and buyout interest.